NASDAQ Infectious Diseases Market News

Spero Therapeutics Initiates Clinical Program for Oral Carbapenem SPR994

Clinical study to evaluate potential first ever orally administered carbapenem being developed for multi-drug ...

[sam_pro id=0_12 codes="true"]
[sam_pro id=0_6 codes="false"]